Article
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
ESMO open - 1 Feb 2026
Piha-Paul S A, De La Fuente M, Iwamoto F, Zhu J-J, Nagpal S, Braiteh F, Chandra S, Fu Y, Chen C, Yang Z, Tsai K K
Abstract excerpt
BACKGROUND: ABM-1310 is an investigational, orally bioavailable BRAF V600 inhibitor with high blood-brain barrier (BBB) penetration. PATIENTS AND METHODS: This first-in-human, phase I trial evaluated patients with BRAF V600-mutated advanced solid tumors, including brain metastases (≤3 cm) and primary central nervous system (CNS) tumors. Patients received ABM-1310 monotherapy [25-250 mg twice a day (b.i.d.); Parts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.